Aptar Digital Health’s acquisition of Healint builds on an existing collaboration between the two companies, aimed at enhancing the management and treatment of Central Nervous System (CNS) diseases and immune conditions


Aptar Digital Health acquires Healint. (Credit: National Cancer Institute on Unsplash)

Aptar Digital Health, a division of Aptar Pharma, has acquired AI-powered healthcare solutions provider Healint to expand its neurology portfolio and strengthen its global footprint.

The acquisition builds on an existing collaboration between Healint and Aptar Digital Health, aimed at enhancing the management and treatment of Central Nervous System (CNS) and immune conditions.

Established in 2013, Healint specialises in virtual clinical studies, real-world evidence, and patient registries platform, and has developed the Migraine Buddy and Clarrio mobile apps.

It enables multimodal health and Quality of Life (QoL) tracking and clinically validated data collection, along with self-input and sensor data, interpreted through its in-house AI technology.

The company generates real-world evidence to help patients, physicians, and researchers improve treatment outcomes and expedite clinical trials.

Healint CEO and founder Stated François Cadiou said: “We are delighted to join the Aptar Digital Health team to better serve patients, healthcare professionals and pharmaceutical companies.

“This acquisition will accelerate the development of our AI-powered precision medicine SaMD designed to augment existing treatment, thanks to unique datasets and scientific expertise.”

Aptar Digital Health said that the acquisition supports its strategy to expand its capabilities in neurology and strengthen its global footprint for digital health deployment.

The expanded capabilities include patient community management, patient activation, Artificial Intelligence (AI) -based data collection and analysis, and digital diagnostics.

Also, Healint’s ability to conduct clinical studies at a faster pace and global scale will complement its existing solutions, said the digital health company.

Aptar Digital Health will immediately start integrating Healint into operations, with plans to scale up Healint’s platform to adjacent therapeutic indications in neurology and immunology.

Aptar Digital Health president Sai Shankar said: “We are excited to welcome the Healint team and expand Aptar Digital Health’s product portfolio and capabilities to clinical trial management.

“With Healint, we now have the in-house expertise to cover the entire lifecycle of a drug, positioning Aptar Digital Health as a prominent leader in digital health for Central Nervous System conditions.”

Aptar Pharma president Gael Touya said: “Through this acquisition, the combined expertise of Aptar Digital Health and Healint in developing state-of-the-art solutions that empower patients in their disease journey fully aligns with Aptar Pharma’s primary ambition of improving patient experiences and health outcomes.”